These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15623544)

  • 41. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
    Sawhney N; Moses JW; Leon MB; Kuntz RE; Popma JJ; Bachinsky W; Bass T; DeMaio S; Fry E; Holmes DR; Teirstein PS
    Circulation; 2004 Jul; 110(4):374-9. PubMed ID: 15249503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Latif F; Kleiman NS; Cohen DJ; Pencina MJ; Yen CH; Cutlip DE; Moliterno DJ; Nassif D; Lopez JJ; Saucedo JF;
    JACC Cardiovasc Interv; 2009 Jan; 2(1):37-45. PubMed ID: 19463396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term clinical outcomes with the use of a modified provisional jailed-balloon stenting technique for the treatment of nonleft main coronary bifurcation lesions.
    Depta JP; Patel Y; Patel JS; Novak E; Yeung M; Zajarias A; Kurz HI; Lasala JM; Bach RG; Singh J
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):E637-46. PubMed ID: 23420654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.
    Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H
    J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Chieffo A; Meliga E; Latib A; Park SJ; Onuma Y; Capranzano P; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Kim YH; Buszman PE; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capodanno D; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2012 Jul; 5(7):718-27. PubMed ID: 22814776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents.
    Kubo M; Miyoshi T; Oe H; Ohno Y; Nakamura K; Ito H
    BMC Cardiovasc Disord; 2015 Sep; 15():102. PubMed ID: 26399321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trial of everolimus-eluting stents or bypass surgery for coronary disease.
    Park SJ; Ahn JM; Kim YH; Park DW; Yun SC; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Choo SJ; Chung CH; Lee JW; Cohen DJ; Yeung AC; Hur SH; Seung KB; Ahn TH; Kwon HM; Lim DS; Rha SW; Jeong MH; Lee BK; Tresukosol D; Fu GS; Ong TK;
    N Engl J Med; 2015 Mar; 372(13):1204-12. PubMed ID: 25774645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefits on coronary restenosis from elective paclitaxel-eluting stent implantation in patients aged 75 years and older.
    Sardella G; De Luca L; De Persio G; Colantonio R; Petrolini A; Conti G; Fedele F
    J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):494-8. PubMed ID: 17568281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
    Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Lindsey JB; Mauri L; Cutlip DE; Kleiman NS;
    Circ Cardiovasc Interv; 2012 Dec; 5(6):772-82. PubMed ID: 23093553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ischemia-driven target vessel revascularization after-primary percutaneous coronary intervention: patients at risk and their outcomes.
    Mehta RH; Harjai KJ; Boura J; O'Neill W; Grines CL;
    J Interv Cardiol; 2005 Jun; 18(3):149-54. PubMed ID: 15966917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term outcome after drug-eluting stents implantation: target lesion versus nontarget lesion repeated intervention.
    Fineschi M; Zacà V; Gori T; Casini S; Sinicropi G; Pierli C
    Int J Cardiol; 2010 Nov; 145(2):322-324. PubMed ID: 20051300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic clinical and angiographic characteristics for the development of a new significant lesion in remote segments after successful percutaneous coronary intervention.
    Tsiamis E; Toutouzas K; Synetos A; Karambelas J; Karanasos A; Demponeras C; Drakopoulou M; Stefanadi E; Tsioufis C; Tousoulis D; Stefanadis C
    Int J Cardiol; 2010 Aug; 143(1):29-34. PubMed ID: 19211162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention.
    van Gaal WJ; Ponnuthurai FA; Selvanayagam J; Testa L; Porto I; Neubauer S; Banning AP
    Int J Cardiol; 2009 Jun; 135(1):60-5. PubMed ID: 18582969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Percutaneous coronary interventions in cardiac allograft vasculopathy: a single-center experience.
    Colombo P; Bruschi G; Sacco A; Oreglia J; De Marco F; Colombo T; Botta L; Macera F; Turazza F; Frigerio M; Martinelli L; Klugmann S
    Transplant Proc; 2010 May; 42(4):1286-90. PubMed ID: 20534283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study.
    Mazzone A; Parri MS; Giannessi D; Ravani M; Vaghetti M; Altieri P; Casalino L; Maltinti M; Balbi M; Barsotti A; Berti S
    Coron Artery Dis; 2011 May; 22(3):179-87. PubMed ID: 21407077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression of nonculprit plaque stenosis following successful percutaneous intervention.
    Bunch TJ; Rihal CS; Gumina RJ; Cooper L; Caplice NM
    Angiology; 2008; 59(2):236-9. PubMed ID: 18388075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progression of coronary artery atherosclerosis after acute myocardial infarction: an angiographic study.
    Hawranek M; Gasior M; Gierlotka M; Wilczek K; Lekston A; Szygula-Jurkiewicz B; Spatuszko A; Polonski L
    J Invasive Cardiol; 2010 May; 22(5):209-15. PubMed ID: 20440036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-human leukocyte antigen antibodies are associated with restenosis after percutaneous coronary intervention for cardiac allograft vasculopathy.
    McKay M; Pinney S; Gorwara S; Burke EM; Sciacca RR; Apfelbaum M; Mancini D; Itescu S; Rabbani LE
    Transplantation; 2005 Jun; 79(11):1581-7. PubMed ID: 15940049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.